Skip to main content
Clinical Trials/NCT05890885
NCT05890885
Completed
Not Applicable

The Effect of Home-Based Transcranial Direct Current Stimulation on Fatigue in Multiple Sclerosis

Assistance Publique - Hôpitaux de Paris1 site in 1 country10 target enrollmentSeptember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fatigue in Multiple Sclerosis
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
10
Locations
1
Primary Endpoint
Tiredness
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

The available therapeutic strategies for Multiple Sclerosis (MS)-related symptoms are usually faced with limited efficacy and numerous side effects. Patients with MS frequently suffer from fatigue, affective symptoms, and cognitive deficits.

Detailed Description

For these reasons, non-invasive brain stimulation (NIBS) techniques, namely transcranial direct current stimulation (tDCS) might be of help in this context. tDCS is a new NIBS technique with a good safety profile, easy implementation, good patients' tolerance and little or no adverse effects. tDCS uses low levels of constant current delivered to specific brain area via sponge electrodes placed on the scalp. tDCS modifies the polarization of the exposed neuronal circuits. Indeed, it modulates the spontaneous neuronal excitability and activity by a tonic depolarization or hyperpolarization of resting membrane potential. Therefore, applying a home-based intervention is of interest in a population suffering from high levels of physical disability prohibiting them from frequently coming to seek care at the hospital

Registry
clinicaltrials.gov
Start Date
September 1, 2022
End Date
April 20, 2023
Last Updated
3 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Definite MS diagnosis according to the 2017 McDonald criteria
  • Fatigue since more than 6 months as assessed by fatigue severity scale (FSS\>5)
  • Age between 18 and 75 years.
  • Stable pharmacological and physical treatment since at least one month
  • Affiliation to the social security regimen
  • Signature of the informed consent
  • Ability of the patient to understand the instructions for use of the pacemaker to ensure safe use

Exclusion Criteria

  • Relapses within the last two months
  • Active medical device implanted
  • Intracranial metal implants
  • Craniotomy, cranial trepanation, aneurysm
  • Uncontrolled epilepsy
  • Non-weaned alcoholism, sleep debt
  • Expanded disability status scale ≥ 6.5
  • Severe depression based on Beck Depression inventory (BDI\>19)
  • Daytime sleepiness based on Epworth Sleepiness Scale (ESS\> 11)
  • Other neurologic and psychiatric diseases

Outcomes

Primary Outcomes

Tiredness

Time Frame: 12 weeks

Modified Fatigue Impact Scale (MFIS): cognitive (10 items), physical (9 items) and psychosocial fatigue (2 items). It is a shortened version of the Fatigue Impact Scale that contains 21 of the original 40 items.

Secondary Outcomes

  • Anxiety(12 weeks)
  • Depression(12 weeks)
  • Alexithymia(before and after each stimulation period (active and simulated) and four weeks later (four weeks after the last stimulation session of each period).)
  • Cognitive functions(12 weeks)
  • MSQOL scale(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials